Drugs / CD137L-DC-EBV-VAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03282617 | Aug 2017 → Aug 2019 | nasopharyngeal carcinoma | National University Hospital, Singapore | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD137L-DC-EBV-VAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03282617 ↗ |
| Action | Activate | “The investigators have developed in the laboratory a highly effective dendritic cell which is primed to activate T cells with the Epstein-Barr virus (EBV) proteins.” NCT03282617 ↗ |
| Modality | Cell therapy | “product made from one of our own immune system cells (dendritic cell, DC)” NCT03282617 ↗ |